Index removals put Adaptive Biotechnologies in focus

Adaptive Biotechnologies (ADPT) has been removed from several Russell indexes, including the Russell 3000E and Russell Microcap series, a change that can reshape how index-linked investors gain exposure to the stock.

At a share price of US$20.16, Adaptive Biotechnologies has seen a 20.7% 1 month share price return and a 50.5% 3 month share price return. The 1 year total shareholder return of 69.0% points to strong longer term momentum even as the stock has recently fallen 3.2% in a day and 9.9% over the past week around the Russell index removals.

If index changes have you rethinking sector exposure, this could be a good moment to scan for other healthcare and immunology plays using our healthcare focused AI stocks screener, 40 healthcare AI stocks

Adaptive Biotechnologies now trades only a fraction below the average analyst target and at a wider discount to some intrinsic value estimates. This raises the question of where a reasonable fair value range actually sits after this index driven swing.

Most Popular Narrative: 10% Overvalued

With Adaptive Biotechnologies trading at $20.16 against a most widely followed fair value estimate of $20.14, the narrative sits almost exactly in line with the market price while still leaning on a very growth heavy story.

Marked improvement in profitability, with the MRD segment now EBITDA positive and company-wide cash burn improving 36% year-over-year, signals the business reaching scale and positions Adaptive for operating leverage and expanding net margins as revenue continues to rise.

Read the complete narrative. Read the complete narrative.

Want to see what underpins that near match between fair value and share price? The narrative leans on brisk revenue expansion, a sharp margin reset and a rich future earnings multiple. Curious how those moving parts are combined into one valuation story that still calls Adaptive Biotechnologies overvalued by around 10%?

Result: Fair Value of $20.14 (OVERVALUED)

However, there is still meaningful risk that ongoing losses and potential pricing or reimbursement setbacks could limit the growth and margin assumptions behind the Adaptive Biotechnologies narrative.

Another View on Adaptive Biotechnologies' Valuation

The most popular narrative has Adaptive Biotechnologies looking around 10% overvalued versus a US$20.14 fair value, yet the SWS DCF model paints a different picture. On that view, the stock at US$20.16 trades about 12.5% below an estimated future cash flow value of US$23.04. Which story do you lean toward?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Adaptive Biotechnologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this combination of optimism and concern around Adaptive Biotechnologies leaves you undecided, take time to review the full picture and consider both sides. For a concise summary of the key positives and key watchpoints, start with the 3 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Adaptive Biotechnologies?

Once you have formed a view on Adaptive Biotechnologies, you can widen your watchlist with a few focused stock ideas that match different investing styles and risk levels.

• Target resilient balance sheets by scanning companies with strong finances and steady fundamentals using the solid balance sheet and fundamentals stocks screener (47 results).
• Look for potential mispricings by checking out the 44 high quality undervalued stocks, which highlights companies whose fundamentals you can compare with their current market prices.
• Identify early stage opportunities by reviewing the 20 elite penny stocks with strong financials, which focuses on smaller market caps and lets you filter for specific financial traits in minutes.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.